4.8 Article

Bioinformatic identification of proteins with tissue-specific expression for biomarker discovery

期刊

BMC MEDICINE
卷 10, 期 -, 页码 -

出版社

BMC
DOI: 10.1186/1741-7015-10-39

关键词

bioinformatics; biomarkers; tissue-specific proteins

资金

  1. Mount Sinai Hospital

向作者/读者索取更多资源

Background: There is an important need for the identification of novel serological biomarkers for the early detection of cancer. Current biomarkers suffer from a lack of tissue specificity, rendering them vulnerable to non-disease-specific increases. The present study details a strategy to rapidly identify tissue-specific proteins using bioinformatics. Methods: Previous studies have focused on either gene or protein expression databases for the identification of candidates. We developed a strategy that mines six publicly available gene and protein databases for tissue-specific proteins, selects proteins likely to enter the circulation, and integrates proteomic datasets enriched for the cancer secretome to prioritize candidates for further verification and validation studies. Results: Using colon, lung, pancreatic and prostate cancer as case examples, we identified 48 candidate tissue-specific biomarkers, of which 14 have been previously studied as biomarkers of cancer or benign disease. Twenty-six candidate biomarkers for these four cancer types are proposed. Conclusions: We present a novel strategy using bioinformatics to identify tissue-specific proteins that are potential cancer serum biomarkers. Investigation of the 26 candidates in disease states of the organs is warranted.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Editorial Material Medical Laboratory Technology

Theranos revisited: the trial and lessons learned

Eleftherios P. Diamandis, Karl J. Lackner, Mario Plebani

CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2022)

Editorial Material Medicine, General & Internal

From Camille Nουσ to Apollonian and the Dionysian scientists

Panos Macheras, Caitlin Di Paolo, Yanna Pusica, Eleftherios P. Diamandis

DIAGNOSIS (2022)

Letter Medical Laboratory Technology

Prognostic significance of blood-based multi-cancer detection in plasma cell-free DNA

Oscar D. Pons-Belda, Amaia Fernandez-Uriarte, Annie Ren, Eleftherios P. Diamandis

CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2022)

Editorial Material Oncology

Cancer Screening Companies Are Rapidly Proliferating: Are They Ready for Business?

Amaia Fernandez-Uriarte, Oscar D. Pons-Belda, Eleftherios P. Diamandis

Summary: Cancer screening has been an important field of research. Traditional biomarkers are not suitable for population screening. Circulating tumor DNA has emerged as a promising new marker for cancer, but there are still challenges and the accuracy of new screening tests needs further definition.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2022)

Article Biochemical Research Methods

Transcriptome profiling and proteomic validation reveals targets of the androgen receptor signaling in the BT-474 breast cancer cell line

Stella K. Vasiliou, Panagiota S. Filippou, Sergi Clotet-Freixas, Antoninus Soosaipillai, Ihor Batruch, Foivos Viktor Tsianos, Ana Konvalinka, Eleftherios P. Diamandis

Summary: This study found that AR regulates the metabolism of BT-474 cells by affecting the expression of a large number of genes and proteins. Further pathway analysis suggests that the androgen receptor acts as a tumor suppressor in BT-474 cells.

CLINICAL PROTEOMICS (2022)

Letter Medicine, General & Internal

Convoluted molecular maze of neprilysin

Eleftherios P. Diamandis, Sok-Ja Janket, Harry A. Conte

DIAGNOSIS (2022)

Letter Medical Laboratory Technology

A new method for early cancer detection based on platelet transcriptomics will have low positive predictive value

Eleftherios. P. P. Diamandis

CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2023)

Article Medical Laboratory Technology

Multiplex proteomics using proximity extension assay for the identification of protein biomarkers predictive of acute graft-vs.-host disease in allogeneic hematopoietic cell transplantation

Ivan Pasic, Annie H. Ren, Ram Vasudevan Nampoothiri, Ioannis Prassas, Jeffrey H. Lipton, Jonas Mattsson, Eleftherios P. Diamandis, Fotios V. Michelis

Summary: Using a novel multiplex antibody-based proximity extension assay, researchers identified serum proteins, including SLAMF7, IL-1ra, BTN3A2, and DAB2, that may potentially serve as biomarkers for acute graft-vs.-host disease.

CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2023)

Article Medical Laboratory Technology

Mucin 13 (MUC13) as a candidate biomarker for ovarian cancer detection: potential to complement CA125 in detecting non-serous subtypes

Annie H. Ren, Panagiota S. Filippou, Antoninus Soosaipillai, Lampros Dimitrakopoulos, Dimitrios Korbakis, Felix Leung, Vathany Kulasingam, Marcus Q. Bernardini, Eleftherios P. Diamandis

Summary: This study explored the potential of using MUC13 as an ovarian cancer biomarker to complement CA125. The results showed that MUC13 could be used to detect non-serous ovarian carcinoma and early-stage disease, in addition to CA125.

CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2023)

Review Biochemistry & Molecular Biology

The roles of proteases in prostate cancer

Hannu Koistinen, Ruusu-Maaria Kovanen, Morley D. Hollenberg, Antoine Dufour, Evette S. Radisky, Ulf-Hakan Stenman, Jyotsna Batra, Judith Clements, John D. Hooper, Eleftherios Diamandis, Oliver Schilling, Antti Rannikko, Tuomas Mirtti

Summary: Since the proposition of the pro-invasive activity of proteolytic enzymes over 70 years ago, several roles for proteases in cancer progression have been established. About half of the 473 active human proteases are expressed in the prostate and many of the most well-characterized members of this enzyme family are regulated by androgens, hormones essential for development of prostate cancer. Most notably, several kallikrein-related peptidases, including KLK3 (prostate-specific antigen, PSA), the most well-known prostate cancer marker, and type II transmembrane serine proteases, such as TMPRSS2 and matriptase, have been extensively studied and found to promote prostate cancer progression. Recent findings also suggest a critical role for proteases in the development of advanced and aggressive castration-resistant prostate cancer (CRPC). Perhaps the most intriguing evidence for this role comes from studies showing that the protease-activated transmembrane proteins, Notch and CDCP1, are associated with the development of CRPC.

IUBMB LIFE (2023)

Letter Medical Laboratory Technology

Please do not call it Theranos

Eleftherios P. Diamandis

CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2023)

Article Oncology

Prognostic impact of kallikrein-related peptidase transcript levels in prostate cancer

Timo-Pekka K. Lehto, Ruusu-Maaria Kovanen, Susanna Lintula, Adrian Malen, Carolin Sturenberg, Andrew Erickson, Olli-Pekka Pulkka, Ulf-Hakan Stenman, Eleftherios P. Diamandis, Antti Rannikko, Tuomas Mirtti, Hannu Koistinen

Summary: This study aimed to investigate the mRNA levels and prognostic impact of all 15 human kallikrein-related peptidases (KLKs) and their targets, proteinase-activated receptors (PARs), in surgically treated prostate cancer (PCa). The results showed that the expression of KLK2, KLK3, KLK4, and KLK15 was closely associated with tumor aggressiveness and prognosis, suggesting their potential as prognostic biomarkers for PCa.

INTERNATIONAL JOURNAL OF CANCER (2023)

Letter Medical Laboratory Technology

Chatbot GPT can be grossly inaccurate

Eleftherios P. Diamandis

CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2023)

Letter Medicine, General & Internal

Convicting a wrong molecule?

Sok-Ja Janket, Jukka H. Meurman, Eleftherios P. Diamandis

DIAGNOSIS (2023)

Review Medicine, General & Internal

Tumor heterogeneity: how could we use it to achieve better clinical outcomes?

Arsani Yousef, Lucianna Ghobrial, Eleftherios P. Diamandis

Summary: Tumors vary in location, tissue type, and histological subtype. This review highlights current classification schemes for tumor heterogeneity and discusses its clinical significance. New molecular techniques offer affordable assessment of tumor heterogeneity, potentially revolutionizing cancer diagnosis and treatment. Standardized and reproducible assessment methods are needed to fully realize the benefits of tumor heterogeneity.

DIAGNOSIS (2023)

暂无数据